Robert Yarchoan (born 1950) is a medical researcher who played an important role in the development of the first effective drugs for AIDS. He is the Chief of the HIV and AIDS Malignancy Branch in the NCI and also coordinates AIDS and AIDS malignancy research throughout the NCI as Director of the Office of HIV and AIDS Malignancy (OHAM).
Education and career
Dr. Yarchoan was raised in Oceanside, New York and graduated from Amherst College in 1971. He subsequently received his M.D. from the University of Pennsylvania and completed an internship and residency in internal medicine at the University of Minnesota and a fellowship in Immunology in the Metabolism Branch of the NCI. After completing his training he joined the laboratory of Dr. Samuel Broder. In 1991 he was appointed to be a Section Chief of the Medicine Branch and in 1996 he named chief of the newly formed HIV and AIDS Malignancy Branch. Dr. Yarchoan was also appointed to be the first director of the NCI Office of HIV and AIDS Malignancy (OHAM) in 2007, which supervises all HIV/AIDS and AIDS malignancy research within the NCI.
Medical and Research Achievements
Along with his colleagues Drs. Samuel Broder and Hiroaki Mitsuya in the National Cancer Institute (NCI), he co-developed the first effective treatments for HIV/AIDS. With his colleagues, he conducted the first clinical trials of zidovudine (AZT), didanosine (ddI), zalcitabine (ddC), and lamivudine (3TC). These trials were the first to demonstrate that administration of anti-retroviral drugs could reverse the declines in CD4 cells and immunologic impairment caused by human immunodeficiency virus (HIV) infection. The development of these drugs was a breakthrough in AIDS therapy, and zidovudine, didanosine, and lamivudine remain in widespread use and are included in the World Health Organization's "Essential Drugs List", which is a list of minimum medical needs for a basic health care system. Dr. Yarchoan also conducted the first trials of combination anti-HIV therapy. His research efforts have also focused on AIDS malignancies, focusing on the pathogenesis and treatment of Kaposi's sarcoma and other virus-associated tumors. He led the first clinical studies showing that paclitaxel was an effective therapy for Kaposi's sarcoma and that thalidomide has activity in this disease. With his colleagues at NCI, he also identified a new disease called interleukin-6 syndrome, caused by Kaposi’s sarcoma-associated herpesvirus (KSHV) in some people with HIV/AIDS.
Awards and honors
Dr. Yarchoan has received many awards including the Assistant Secretary for Health Award and the U.S. Public Health Service Outstanding Service Medal. He also was awarded the first National Institutes of Health (NIH) World AIDS Day Award in December, 2006 for his work in developing drugs for AIDS. In November, 2007, he was awarded the NCI HIV/AIDS Research Excellence Award along with his colleagues, Drs. Samuel Broder, Robert C. Gallo, and Hiroaki Mitsuya. In October 2009, he received the National Cancer Institute Director's Awards of Merit for leadership in promoting and supporting research in HIV/AIDS and HIV-associated malignancies at the National Cancer Institute.
Dr. Yarchoan is a co-editor of several journals. He is a member of the American Society for Clinical Investigation and has been inducted as a Fellow of the American Association for the Advancement of Science (AAAS).
In 2013, Dr. Yarchoan received an honorary degree for his contributions to HIV/AIDS research from his alma mater, Amherst College
- NIH Bio and Oral History of Dr. Yarchoan describing development of AIDS drugs
- Website of the HIV and AIDS Malignancy Branch in the NCI
- Report of NIH Office of Technology Transfer on ddI Development and Licensing
- Website of the NCI Office of HIV and AIDS Malignancy
- Yarchoan R, Mitsuya H, Broder S. AIDS therapies. Scientific American 1988;259(4):110-9
- Saville, M.W., Lietzau, J., Pluda, J.M., Feuerstein, I., Odom, J., Wilson, W.H., Humphrey, R.W., Feigal, E., Steinberg, S.M., Broder, S., Yarchoan R. 1995. Treatment of HIV-associated Kaposi's sarcoma with paclitaxel. Lancet 346:26-28.
- NCI Scientists Identify a New Inflammatory Syndrome